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ABSTRACT
Objective: This work is designed at finding new structure leads with potential anticonvulsant activities of 4(3H)-quinazolinone pharmacophore 
scaffold.
Methods: A new series of 4(3H)-quinazolinone pharmacophore was designed with substituted moieties possesses different electronic environment 
in the hope of developing potent and safe new effective compounds. In such fashion, in this paper, we report the synthesis and anticonvulsant activity 
(Chemo shock) of N-1(substituted-N-4[(4-oxo-3-phenyl-3, 4-dihydro-quinazoline-2-ylmethyl) semicarbazones 3A-d (1-7), 3B-d (1-7), 3C-d (1-7), 
their chemical structure were characterized using IR, 1H-H NMR, and elemental analysis techniques. Their anticonvulsant activity was evaluated using 
chemicals strychnine, thiosemicarbazide and 4-aminopyridine induced seizure models at a dose of 30, 100, 300 mg/kg unto 2 hrs tests in mice. The 
rotarod assay was performed in mice to evaluate the neurotoxicity of the compounds.
Results: Compounds 3C (d-4), 3B (d-4), and 3A (d-4) were observed to be most feasible to act against glutamate receptor for anticonvulsant activity.
Conclusions: The results obtained revealed that numbers of novel quinazolinone semicarbazone derivatives are effective in chemical to induce 
(chemo shock) model and showing good anticonvulsant activity.
Keywords: Quinazolinone, Semicarbazones, Strychnine, Thiosemicarbazide, 4-aminopyridine, Anticonvulsant activity, Chemo shock.
INTRODUCTION
Epilepsy is regarded as a multifactor and symptomatologically highly 
diversified neurological disorder result from long-lasting plastic 
changes in the brain affecting neurotransmitter release, the properties 
of receptors and channels, synaptic reorganization and astrocyte 
activity. It inflicts more than 60 million people worldwide according 
to epidemiological studies [1,2]. Different chemical classes such as 
hydantoins, barbiturates, benzodiazepines, gamma-amino butyric acid 
(GABA) analogs, dibenzazepines, and carbamates are known to be 
part of anti-epileptic scaffolds [3-8]. Several of these drugs are known 
to act through modulating the GABAergic and glutamate/aspartate 
systems. Glutamate, the major fast excitatory neurotransmitter in the 
brain, play a significant role in brain development, affecting neuronal 
migration, neuronal differentiation, axon genesis, and neuronal 
survival [9,10]. Glutamate activates a number of pharmacologically 
distinct subtypes [11,12] and plays an essential role in long-term 
potentiation [13] brought on the identification that most excitatory 
neurotransmission in the central nervous system (CNS) is mediated 
by glutamate receptors. They are important mediators of a wide 
range of neuronal functions from primary sensory perception to 
cognition [14-17]. Glutamate receptors also play a role in a number 
of neurodegenerative diseases and epilepsy [18]. L-glutamate can be 
synthesized in nerve terminals from a-ketoglutarate (formed from 
gluconeogenesis and the tricarboxylic acid cycle) by the enzyme 
glutamate dehydrogenase, and from glutamine by the glutaminase 
enzyme [19,20]. The release of glutamate gets elevated in epilepsy. 
The majority of antiepileptic drugs reduce the release of excitatory 
glutamate by blocking sodium or calcium channels, activation of 
GABA, inhibition of glutamate receptor, and activation of peroxisome 
proliferator-activated receptor alpha. Epileptic seizures occur when 
the excitability in certain brain circuits exceeds the restraints imposed 
by inhibitory mechanisms [21]. Ionotropic glutamate receptors of 
the AMPA and NMDA are the primary mediators of excitation in the 
CNS [22] and are critical to seizure generation and spread [23]. Less 
is known about the role of kainate receptors (KARs). KARs are also 
ionotropic glutamate receptors which share 40% homology with AMPA 
receptors and 20% homology with NMDA receptors [24] KARs are 
responsible for a portion of glutamate-mediated excitation like AMPA 
and NMDA receptors at some synapses, inducing those in limbic regions 
relevant to epilepsy [25]. Axonal kainate can affect axonal excitability 
leading to ectopic action potentials [26]. Agonist, kainic acid, is a 
powerful convulsant, kainate antagonists would be expected to have 
antiseizure effects [27]. Literature evidence suggests that KARs are 
widely distributed in the CNS; represent a major target through which 
the convulsant kainate induces seizures and status epilepticus [28]. 
Various studies in brain regions have demonstrated that KARs 
contribute to postsynaptic excitation of principal neurons [29-32] 
and interneurons [33,34] and also act presynaptically to modulate 
GABA [35] and glutamate [36] release. Some authors reported that 
seizure protection can be achieved through inhibition of KARs [37], 
whereas others have proposed that activation of these receptors is 
a promising antiepileptic strategy [38]. A selective, noncompetitive 
allosteric AMPA-receptor antagonist, perampanel, was approved for 
adjunctive epilepsy treatment [39,40] and topiramate was approved 
to act at AMPA/KARs at high concentrations [41]. Glutamate receptor 
inhibitors (GRIs) are structurally diverse group of compounds binds 
to the glutamate receptor and interacts with a specific allosteric 
non-substrate binding pocket site. GRIs non-competitively inhibits 
glutamate receptor, blocks its mechanism and makes it unable to 
bind glutamate. 4(3H)-quinazolinones are one of the most frequently 
encountered heterocycles in medicinal chemistry reported having 
diverse pharmacological activities. A literature survey disclosed 
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that the presence of a substituted aromatic ring at position 3 is the 
necessary requirement for the anticonvulsant activities of compounds 
such as methaqualone, etaqualone, mecloqualone, mebroqualone, and 
afloqualone. Methaqualone was an important compound in the field 
of synthetic anticonvulsant, possessed quinazoline core which was 
responsible for its activity [42]. Literature survey revealed that the 
semicarbazones have documented consistent advances in the design 
of novel anticonvulsant agents [43,44] and the structure-activity 
relations (SAR) from accumulated semicarbazone anti-epileptics 
indicate that compounds providing handle for (a) aryl binding site with 
a hydrophobic group, (b) hydrogen bonding domain, (c) lone pair of 
electrons, and (d) moieties for hydrophobic interaction are favorable 
for the activity. The aim of this study, therefore to synthesize new 
series of quinazolinone semicarbazone derivatives with the purpose 




Melting points were determined in open capillary tubes and are 
uncorrected. The homogeneity of the compounds was monitored by 
thin layer chromatography (TLC) using silica gel G as a stationary 
phase and visualized by iodine vapors. Solvent system was 
chloroform:methanol (9:1). Microanalysis of the compounds was done 
on Perkin-Elmer model 240 analyzer, and the values found within ±0.4% 
of the theoretical values. 1H-H NMR spectra were recorded on DPX-
300 H NMR spectrometer and BRUKER-400 Ultra shieldTM spectrometer. 
Chemical shifts (δ) are expressed in ppm relative to tetramethylsilane. 
The IR spectra were recorded in KBr pellets on BIO-RAD FTS, IR 
spectrophotometer. All the chemicals and solvents used were procured 
from Merck (India), S. D. Fine Chemicals (India) & Rankem (India).
General procedure for synthesis of compounds 3A-d (1-7), 3B-d 
(1-7), 3C-d (1-7) derivatives
Compounds 3A-d (1-7), 3B-d (1-7), 3C-d (1-7), were synthesized 
as describe in Schemes 1 and 2. The N-chloroacetyl anthranilic acid 
analog 2 was obtained by reacting anthranilic acid (1.45 mmol) 
1 with chloroacetyl chloride (21.9 mmol) in the presence of sodium 
bicarbonate in tetrahydrofuran at 0-5°C. Analogue 2 (4.59 mmol) 
was further refluxed with substituted anilines (5.51 mmol) in the 
presence of phosphorous oxychloride in tetrahydrofuran for 1 h to 
yield 2-chloromethyl-3-sustituted aryl-3H-quinazoline-4-one 3A, 3B, 
3C derivatives Scheme 1. Compounds 3A, 3B, 3C were converted to 
corresponding amines derivatives 3A-a, 3B-a, 3C-a by reaction with 
ammonia which was further reacted with sodium cyanate in the 
presence of catalytic amount of glacial acetic acid to produce urea 
derivatives 3A-b, 3B-b, 3C-b as per previously known urea preparation 
method [45-47]. Different substituted semicarbazides 3A-c, 3B-c, 
3C-c were obtained by condensation of these urea derivatives with 
hydrazine hydrate in ethanol under basic condition. The semicarbazone 
3A-d (1-7), 3B-d (1-7), 3C-d (1-7), derivatives were prepared by reaction 
of the appropriate aryl/cycloalkyl aldehyde or ketone listed in Table 1 
with the corresponding semicarbazide in glacial acetic acid Scheme 2. 
Final compounds were washed with brine solution and treated with 
Na2SO4. TLC was performed throughout the reactions to optimize the 
reactions for purity and completion. The physical data for the newly 
synthesized compounds are presented in Table 2. The formation of the 
title compounds was confirmed by its IR and 1H-H NMR spectral studies.
Characterization of N-1(substituted-N-4[(4-oxo-3-phenyl-3, 4-dihydro-
quinazoline-2-ylmethyl) semicarbazones derivatives are as follows:
2(chloromethyl)3phenylquinazolin4(3H)one(3A)IR (KBr, cm1) 
3382 (ArH), 1680 (C=C), 1580 (C=N), 1550 (C-C), 1700 (C=O), 
1260 (CH2Cl), 1H NMR (300 MHz, CDCl3, ppm, δ): 6.75 (m, 4H, ArH), 
7.20 (m, 5H, ArH), 2.70 (s, 2H, CH2), anal. Calcd for; C15H11ClN2O (270.71) 
(%): Found=C (66.55) H (4.10) N (10.35) calculated = C (66.61) H (4.31) 
N (10.38).
2-(chloromethyl)-3-(4-chlorophenyl) quinazolin-4(3H)-one (3B) 
IR (KBr, cm−1) 3387 (Ar-H), 1688 (C=C), 1600 (C=N), 1555 (C-C), 
1705 (C=O), 1263 (CH2Cl), 1H NMR (300 MHz, CDCl3, ppm, δ): 6.71 
(m, 4H, ArH), 7.23 (m, 5H, ArH), 2.71 (s, 2H, CH2), anal. Calcd for; 
C15H10Cl2N2O (305.16) (%): Found = C (59.04) H (3.30) N (9.18) 
calculated = C (59.34) H (3.42) N (9.39).
2-(chloromethyl)-3-(4-nitrophenyl) quinazolin-4(3H)-one (3C) 
IR (KBr, cm−1) 3384 (Ar-H), 1685 (C=C), 1590 (C=N), 1554 (C-C), 
1710 (C=O), 1265 (CH2Cl), 1H NMR (300 MHz, CDCl3, ppm, δ): 6.70 
(m, 4H, Ar-H), 7.25 (m, 5H, ArH), 2.73 (s, 2H, CH2), anal. Calcd for; 
C15H10ClN3O3(315.71) (%): Found = C (57.06) H (3.19) N (13.31)
calculated = C (57.16) H (3.10) N (13.50).
( 2 E ) - 2 - ( 4 - c h l o r o b e n z y l i d e n e ) - N - [ ( 4 - o x o - 3 - p h e n y l - 3 , 4 -
dihydroquinazolin-2-yl)methyl]hydrazinecarboxamide 3A(d-1) IR 
(KBr, cm−1) 3382 (Ar-H), 1687 (C=C), 1610 (C=N), 1551 (C-C), 1722 
(C=O), 3360 (N-H), 1090 (Ar-Cl), 1665 (C=N str of NHN=C); 1H NMR 
(300 MHz, CDCl3, ppm, δ): 6.72 (m, 4H, Ar-H), 7.22 (m, 5H, ArH), 
2.69 (s, 2H, CH2) 4.49 (s, 1H, NH), 11.32 (s, 1H, CONH), anal. Calcd 
for; C23H18ClN5O2 (431.11) (%): Found = C (63.96) H (4.20) N (16.22) 
calculated = C (63.94) H (4.24) N (16.20).
N-1(acetophenyl)-N-4[4-oxo-3-phenyl-3,4-dihydro-quinaline-2-
ylmethyl)semicarbazone 3A(d-2) IR (KBr, cm−1) 3380 (Ar-H), 1689 
(C=C), 1610 (C=N), 1559 (C-C), 1711 (C=O), 3359 (N-H), 1669 (C=N str 
of NHN=C); 1H NMR (300 MHz, CDCl3, ppm, δ): 6.80 (m, 4H, Ar-H), 7.51 
(m, 5H, ArH), 2.68 (s, 2H, CH2) 4.40 (s, 1H, NH), 11.36 (s, 1H, CONH), 
anal. Calcd for; C24H21N5O2 (411.16) (%): Found = C (70.06) H (5.14) N 
(17.02) calculated = C (70.16) H (5.24) N (17.22).
N-1(p-nitro-acetophenyl)-N-4[4-oxo-3-phenyl-3,4-dihydro-quinaline-
2ylmethyl)semicarbazone3A(d-3) IR (KBr, cm−1) 3384 (Ar-H), 1690 
(C=C), 1620 (C=N), 1549 (C-C), 1712 (C=O), 3351 (N-H), 1480 (N-O), 
1670 (C=N str of NHN=C); 1H NMR (300 MHz, CDCl3, ppm, δ): 6.69 
Scheme 1: Preparation procedure of different aromatic amine derivatives of N-chloro anthranilic acid
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(m, 4H, Ar-H), 7.57 (m, 5H, ArH), 2.64 (s, 2H, CH2) 4.39 (s, 1H, NH), 
11.37 (s, 1H, CONH), anal. Calcd for; C24H20N6O4 (456.15) (%): Found = C 
(63.15) H (4.42) N (18.41) calculated = C (63.34) H (4.56) N (18.31).
N-1(menthone)-N-4[(4-oxo-3-phenyl-3,4-dihydro-quinazoline-2-
ylmethyl)semicarbazone 3A(d-4) IR (KBr, cm−1) 3383 (Ar-H), 1691 
(C=C), 1614 (C=N), 1550 (C-C), 1710 (C=O), 3350 (N-H), 1672 (C=N 
str of NHN=C); 1H NMR (300 MHz, CDCl3, ppm, δ): 6.71 (m, 4H, Ar-H), 
7.53 (m, 5H, ArH), 2.90 (s, 2H, CH2) 4.63 (s, 1H, NH), 11.39 (s, 1H, 
CONH), 1.33 (s, 3H, CH3), 1.08 (s, 3H, CH3), 1.23 (s, 3H, CH3); anal. Calcd 
for; C26H31N5O2 (447.16) (%): Found = C (70.09) H (7.01) N (15.72) 
calculated = C (70.11) H (7.12) N (15.68).
N-1(camphor)-N-4[(4-Oxo-3phenyl-3,4-dihdroquinazolin-2-ylmethyl)-
semicarbazone 3A(d-5) IR (KBr, cm−1) 3381 (Ar-H), 1690 (C=C), 1619 
(C=N), 1560 (C-C), 1720 (C=O), 3358 (N-H), 1678 (C=N str of NHN=C); 
1H NMR (300 MHz, CDCl3, ppm, δ): 6.78 (m, 4H, Ar-H), 7.63 (m, 5H, ArH), 
2.85 (s, 2H, CH2) 4.66 (s, 1H, NH), 11.49 (s, 1H, CONH), 1.39 (s, 3H, CH3); 
anal. Calcd for; C26H29N5O2 (298.16) (%): Found = C (69.32) H (4.92) N 
(18.66) calculated = C (69.42) H (4.88) N (18.72).
N-1(furfuraldehyde)-N-4[(4-Oxo-3phenyl-3,4-dihdroquinazolin-2-
ylmethyl)-semicarbazone 3A(d-6) IR (KBr, cm−1) 3380 (Ar-H), 1655 
(C=C), 1620 (C=N), 1561 (C-C), 1722 (C=O), 3359 (N-H), 1668 (C=N 
str of NHN=C), 1155 (C-O), 1220 (C-O-C); 1H NMR (300MHz, CDCl3, 
ppm, δ): 7.78 (m, 4H, Ar-H), 7.61 (m, 5H, ArH), 2.75 (s, 2H, CH2) 4.50 
(s, 1H, NH), 11.55 (s, 1H, CONH), 6.71 (m, 3H, ArH) 5.48 (s, 1H, CH); 
anal. Calcd for; C21H17N5O3 (387.13) (%): Found = C (65.11) H (4.42) N 
(18.08) calculated = C (65.19) H (4.46) N (18.28).
N-1(benzophenyl)-N-4[(4-Oxo-3phenyl-3,4-dihdroquinazolin-2-
ylmethyl)-semicarbazone 3A(d-7) IR (KBr, cm−1) 3370 (Ar-H), 1650 
(C=C), 1600 (C=N), 1551 (C-C), 1702 (C=O), 3351 (N-H), 1668 (C=N str 
of NHN=C), 1H NMR (300MHz, CDCl3, ppm, δ): 7.81 (m, 4H, Ar-H), 7.41 
(m, 5H, ArH), 2.70 (s, 2H, CH2) 3.40 (s, 1H, NH), 11.45 (s, 1H, CONH), 
7.95 (m, 5H, ArH) 6.48 (m, 5H, ArH); anal. Calcd for; C29H23N5O2 (473.18) 
(%): Found = C (73.56) H (4.90) N (14.79) calculated = C (73.62) 
H (4.97) N (14.68).
N-{[3-(4-chlorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl]methyl}-
semicarbazone 3B(d-1) IR (KBr, cm−1) 3381 (Ar-H), 1688 (C=C), 1622 
(C=N), 1553 (C-C), 1723 (C=O), 3363 (N-H), 1092 (Ar-Cl), 1664 (C=N str 
of NHN=C); 1H NMR (300 MHz, CDCl3, ppm, δ): 6.70 (m, 4H, Ar-H), 7.20 
(m, 5H, ArH), 2.70 (s, 2H, CH2) 4.50 (s, 1H, NH), 11.33 (s, 1H, CONH), 
anal. Calcd for; C23H17Cl2N5O2 (465.07) (%): Found = C (59.08) H (3.64) 
N (15.00) calculated = C (59.24) H (3.67) N (15.02).
N-{[3-(4-chlorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl]methyl}
semicarbazone 3B(d-2) IR (KBr, cm−1) 3384 (Ar-H), 1690 (C=C), 1601 
(C=N), 1560 (C-C), 1713 (C=O), 3362 (N-H), 1670 (C=N str of NHN=C); 
1H NMR (300 MHz, CDCl3, ppm, δ): 6.82 (m, 4H, Ar-H), 7.53 (m, 5H, 
ArH), 2.69 (s, 2H, CH2) 4.42 (s, 1H, NH), 11.39 (s, 1H, CONH), anal. Calcd 
for; C24H20Cl N5O2 (445.13) (%): Found = C (64.60) H (4.48) N (15.69) 
calculated = C (64.65) H (4.52) N (15.71).
N-{[3-(4-chlorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl]methyl}
semicarbazone 3B(d-3) IR (KBr, cm−1) 3385 (Ar-H), 1694 (C=C), 1616 
(C=N), 1544 (C-C), 1710 (C=O), 3356 (N-H), 1483 (N-O), 1674 (C=N str 
of NHN=C); 1H NMR (300 MHz, CDCl3, ppm, δ): 6.70 (m, 4H, Ar-H), 7.59 
(m, 5H, ArH), 2.60 (s, 2H, CH2) 4.38 (s, 1H, NH), 11.34 (s, 1H, CONH), 
anal. Calcd for; C24H19ClN6O4 (490.11) (%): Found = C (58.70) H (3.88) 
N (17.10) calculated = C (58.72) H (3.90) N (17.12).
N-{[3-(4-chlorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl]methyl}
semicarbazone 3B(d-4) IR (KBr, cm−1) 3380 (Ar-H), 1692 (C=C), 1617 
(C=N), 1552 (C-C), 1712 (C=O), 3354 (N-H), 1674 (C=N str of NHN=C); 
1H NMR (300 MHz, CDCl3, ppm, δ): 6.73 (m, 4H, Ar-H), 7.55 (m, 5H, 
ArH), 2.91 (s, 2H, CH2) 4.60 (s, 1H, NH), 11.38 (s, 1H, CONH), 1.35 (s, 3H, 
CH3), 1.06 (s, 3H, CH3), 1.26 (s, 3H, CH3); anal. Calcd for; C23H21ClN5O2 
(470.13) (%): Found = C (63.49) H (4.84) N (16.08) calculated = C 
(63.52) H (4.87) N (16.10).
N-{[3-(4-chlorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl]methyl}-
semicarbazone 3B(d-5) IR (KBr, cm−1) 3383 (Ar-H), 1693 (C=C), 1620 
(C=N), 1563 (C-C), 1723 (C=O), 3359 (N-H), 1676 (C=N str of NHN=C); 
1H NMR (300 MHz, CDCl3, ppm, δ): 6.76 (m, 4H, Ar-H), 7.67 (m, 5H, ArH), 
2.88 (s, 2H, CH2) 4.65 (s, 1H, NH), 11.47 (s, 1H, CONH), 1.38 (s, 3H, CH3); 
anal. Calcd for; C26H29N5O2 (298.16) (%): Found = C (65.30) H (5.88) 
N (14.61) calculated = C (65.33) H (5.90) N (14.65).
N-{[3-(4-chlorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl]methyl}-
semicarbazone 3B(d-6) IR (KBr, cm−1) 3384 (Ar-H), 1656 (C=C), 1626 
(C=N), 1565 (C-C), 1720 (C=O), 3360 (N-H), 1669 (C=N str of NHN=C), 
1159 (C-O), 1225 (C-O-C); 1H NMR (300MHz, CDCl3, ppm, δ): 7.79 
(m, 4H, Ar-H), 7.60 (m, 5H, ArH), 2.73 (s, 2H, CH2) 4.52 (s, 1H, NH), 
11.52 (s, 1H, CONH), 6.70 (m, 3H, ArH) 5.47 (s, 1H, CH); anal. Calcd 
Scheme 2: Preparation procedure of quinazolinone semicarbazone derivatives
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for; C21H16ClN5O3 (421.09) (%): Found = C (59.72) H (3.80) N (16.57) 
calculated = C (59.79) H (3.82) N (16.60).
N-{[3-(4-chlorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl]methyl}-
semicarbazone 3B(d-7) IR (KBr, cm−1) 3373 (Ar-H), 1655 (C=C), 
1608 (C=N), 1559 (C-C), 1709 (C=O), 3357 (N-H), 1669 (C=N str of 
NHN=C), 1H NMR (300MHz, CDCl3, ppm, δ): 7.83 (m, 4H, Ar-H), 7.43 
(m, 5H, ArH), 2.72 (s, 2H, CH2) 3.45 (s, 1H, NH), 11.40 (s, 1H, CONH), 7.92 
(m, 5H, ArH)6.49 (m, 5H, ArH); anal. Calcd for; C29H22ClN5O2 (507.14) 
(%): Found = C (68.51) H (4.33) N (13.77) calculated = C (68.57) 
H (4.37) N (13.79).
N-{[3-(4-nitrophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl]methyl}-
semicarbazone 3C(d-1) IR (KBr, cm−1) 3382 (Ar-H), 1686 (C=C), 1606 
(C=N), 1552 (C-C), 1725 (C=O), 3360 (N-H), 1091 (Ar-Cl), 1665 (C=N str 
of NHN=C); 1H NMR (300 MHz, CDCl3, ppm, δ): 6.71 (m, 4H, Ar-H), 7.24 
(m, 5H, ArH), 2.75 (s, 2H, CH2) 4.54 (s, 1H, NH), 11.35 (s, 1H, CONH), 
anal. Calcd for; C23H17ClN6O4 (476.01) (%): Found = C (57.90) H (3.60) 
N (17.59) calculated = C (57.93) H (3.59) N (17.62).
N-{[3-(4-nitrophenyl)-4-oxo-3, 4-dihydroquinazolin-2-yl] methyl} 
semicarbazone 3C(d-2) IR (KBr, cm−1) 3382 (Ar-H), 1693 (C=C), 1606 
(C=N), 1563 (C-C), 1715 (C=O), 3360 (N-H), 1674 (C=N str of NHN=C); 
Table 1: Different aryl/cycloalkyl aldehyde or ketone used in the preparation of quinazolinone semicarbazone derivatives 3A-d (1-7), 
3B-d (1-7), 3C-d (1-7)
Serial number Compound ID X R R1
1 3A-d-1 -H -H -C6H4Cl
2 3A-d-2 -H -CH3 -C6H5
3 3A-d-3 -H -CH3 -C6H4NO2
4 3A-d-4 -H -H
5 3A-d-5 -H -H
6 3A-d-6 -H -H
7 3A-d-7 -H -C6H5 -C6H5
8 3B-d-1 -Cl -H -C6H4Cl
9 3B-d-2 -Cl -CH3 -C6H5
10 3B-d-3 -Cl -CH3 -C6H4NO2
11 3B-d-4 -Cl -H
12 3B-d-5 -Cl -H
13 3B-d-6 -Cl -H
14 3B-d-7 -Cl -C6H5 -C6H5
15 3C-d-1 -NO2 -H -C6H4Cl
16 3C-d-2 -NO2 -CH3 -C6H5
17 3C-d-3 -NO2 -CH3 -C6H4NO2
18 3C-d-4 -NO2 -H
19 3C-d-5 -NO2 -H
20 3C-d-6 -NO2 -H
21 3C-d-7 -NO2 -C6H5 -C6H5
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1H NMR (300 MHz, CDCl3, ppm, δ): 6.83 (m, 4H, Ar-H), 7.54 (m, 5H, 
ArH), 2.68 (s, 2H, CH2) 4.40 (s, 1H, NH), 11.35 (s, 1H, CONH), anal. Calcd 
for; C24H20N6O4 (456.15) (%): Found = C (63.11) H (4.40) N (18.44) 
calculated = C (63.15) H (4.42) N (18.41).
N-{[3-(4-nitrophenyl)-4-oxo-3, 4-dihydroquinazolin-2-yl] methyl} 
semicarbazone 3C(d-3) IR (KBr, cm−1) 3383 (Ar-H), 1699 (C=C), 1619 
(C=N), 1554 (C-C), 1720 (C=O), 3358 (N-H), 1488 (N-O), 1679 (C=N str 
of NHN=C); 1H NMR (300 MHz, CDCl3, ppm, δ): 6.73 (m, 4H, Ar-H), 7.58 
(m, 5H, ArH), 2.63 (s, 2H, CH2) 4.40 (s, 1H, NH), 11.44 (s, 1H, CONH), 
anal. Calcd for; C24H19N7O6 (501.13) (%): Found = C (57.45) H (3.80) 
N (19.52) calculated = C (57.48) H (3.82) N (19.55).
N-{[3-(4-nitrophenyl)-4-oxo-3, 4-dihydroquinazolin-2-yl] methyl} 
semicarbazone 3C(d-4) IR (KBr, cm−1) 3384 (Ar-H), 1691 (C=C), 1620 
(C=N), 1559 (C-C), 1709 (C=O), 3350 (N-H), 1670 (C=N str of NHN=C); 
1H NMR (300 MHz, CDCl3, ppm, δ): 6.69 (m, 4H, Ar-H), 7.51 (m, 5H, ArH), 
2.89 (s, 2H, CH2) 4.55 (s, 1H, NH), 11.33 (s, 1H, CONH), 1.30 (s, 3H, CH3), 
1.12 (s, 3H, CH3), 1.21 (s, 3H, CH3); anal. Calcd for; C23H21N6O4 (481.16) 
(%): Found = C (62.01) H (4.75) N (18.87) calculated = C (62.01) 
H (4.75) N (18.87).
N-{[3-(4-nitrophenyl)-4-oxo-3, 4-dihydroquinazolin-2-yl]methyl}-
semicarbazone 3C(d-5) IR (KBr, cm−1) 3379 (Ar-H), 1687 (C=C), 1610 
(C=N), 1553 (C-C), 1713 (C=O), 3349 (N-H), 1669 (C=N str of NHN=C); 
1H NMR (300 MHz, CDCl3, ppm, δ): 6.71 (m, 4H, Ar-H), 7.62 (m, 5H, ArH), 
2.89 (s, 2H, CH2) 4.68 (s, 1H, NH), 11.41 (s, 1H, CONH), 1.42 (s, 3H, CH3); 
anal. Calcd for; C25H25N6O4 (473.50) (%): Found = C (63.39) H (5.30) 
N (17.71) calculated = C (63.41) H (5.32) N (17.75).
N-{[3-(4-nitrophenyl)-4-oxo-3, 4-dihydroquinazolin-2-yl] methyl}-
semicarbazone 3C(d-6) IR (KBr, cm−1) 3388 (Ar-H), 1659 (C=C), 
1620 (C=N), 1555 (C-C), 1727 (C=O), 3366 (N-H), 1668 (C=N str of 
NHN=C), 1169 (C-O), 1227 (COC); 1H NMR (300 MHz, CDCl3, ppm, δ): 
7.69 (m, 4H, ArH), 7.65 (m, 5H, ArH), 2.77 (s, 2H, CH2) 4.42 (s, 1H, NH), 
11.42 (s, 1H, CONH), 6.73 (m, 3H, ArH) 5.41 (s, 1H, CH); anal. Calcd 
for; C21H16N6O5 (432.11) (%): Found = C (58.30) H (3.70) N (19.42) 
calculated = C (58.33) H (3.73) N (19.44).
N-{[3-(4-nitrophenyl)-4-oxo-3, 4-dihydroquinazolin-2-yl] methyl}-
semicarbazone 3C (d-7) IR (KBr, cm−1) 3377 (Ar-H), 1665 (C=C), 1600 
(C=N), 1569 (C-C), 1719 (C=O), 3347 (N-H), 1670 (C=N str of NHN=C), 
1H NMR (300MHz, CDCl3, ppm, δ): 7.73 (m, 4H, Ar-H), 7.42 (m, 5H, 
ArH), 2.70 (s, 2H, CH2) 3.41 (s, 1H, NH), 11.37 (s, 1H, CONH), 7.91 (m, 
5H, ArH)6.59 (m, 5H, ArH); anal. Calcd for; C29H22N6O4 (518.17) (%): 




Albino mice of either sex weighing between 25-30 g were used in 
this study. All albino mice employed in this study is approved by 
the Institutional Animal Ethics Committee of NBRI, Lucknow and 
carried out as per CPCSEA guidelines. The animals were kept in 
large spacious hygienic cages during the course of the experimental 
period. The animals had free access to standard commercial diet and 
water ad libitum and were kept in rooms maintained at 22±1°C with 
12 hrs light-dark cycle. The animals were divided into three groups 
of 10 animals each: Group I: Control group (distilled water treated). 
Group II: Test group (were dissolved in polyethylene glycol-400 and 
30, 100, 300 mg/kg i.p. doses), Group III: Standard group, on reference 
drug (diazepam, 10 mg/kg i.p. phenytoin 30 mg/kg i.p.). All the drugs 
were administered 30 minutes before the administration of strychnine 
(1 mg/kg, i.p.) thiosemicarbazide (20 mg/kg, s.c.) and 4-aminopyridine 
(13.3 mg/kg, s.c.). The anticonvulsant screening of the final compounds 




Mice of either sex with a weight of 25-30 g were treated with the 
test compounds or the standards (eg., diazepam 10 mg/kg ip.) by 
an oral or intraperitoneal administration. Controls received the 
vehicle only. 30 minutes prior treatment with a subcutaneous dose of 
1 mg/kg strychnine, test compounds in doses 30, 100; 300 mg/kg i.p. 
was injected. The occurrence of clonic seizures, tonic seizures, and 
death or recovery was recorded after 0.5 hr, 1 hr, 2 hrs and 4 hrs, 
respectively [49].
Thiosemicarbazide induced model
Mice of either sex with a weight of 25-30 g were treated with the test 
compounds or the standard (e.g., diazepam 10 mg/kg i.p.) by the oral 
or intraperitoneal administration. Controls received the vehicle only. 
30 minutes prior treatment with a subcutaneous dose of 20 mg/kg 
thiosemicarbazide, test compounds in doses 30, 100, 300 mg/kg i.p. 
was injected. The occurrence of clonic seizures, tonic seizures, and 
death or recovery was recorded after 0.5 hr, 1 hr, 2 hrs and 4 hrs, 
respectively [50].
4-amino pyridine induced model
Mice of either sex weighing 25-30 g will allow acclimatizing with 
free access to food and water for a 24-hr period before testing. Test 
drugs will administer at a dose of 30, 100, 300 mg/kg body weight 
intraperitoneally (i.p.), 30 minutes prior to subcutaneous injection 
of 4-aminopyridine at a dose of 13.3 mg/kg. Controls treated with 
4-aminopyridine only exhibit characteristic behavioral signs, such 
as hyperreactivity, trembling, intermitted forelimb/hindlimb clones 
followed by hind limb extension, tonic seizures, and death. The 
standard drug phenytoin at a dose of 30mg/kg body weight was taken 
for comparison [51].
Table 2: Physical properties of the final synthesized 
quinazolinone semicarbazone derivatives
Compound ID Molecular 
formula
Log p Melting 
point (°C)
Yield (%)
3A-d-1 C23H18ClN5O2 3.11 266-268 74
3A-d-2 C24H21N5O2 3.33 272-274 70
3A-d-3 C24H20N6O4 3 275-277 72
3A-d-4 C26H31N5O2 3.66 282-284 66
3A-d-5 C26H29N5O2 3.22 284-286 69
3A-d-6 C21H17N5O3 2.89 290-292 68
3A-d-7 C29H23N5O2 3.88 287-289 71
3B-d-1 C23H17Cl2N5O2 3 >300 78
3B-d-2 C24H20ClN5O2 3.22 >300 82
3B-d-3 C24H19ClN6O4 2.89 >300 70
3B-d-4 C23H21ClN5O2 3.44 >300 65
3B-d-5 C26H28ClN5O2 3.11 298-300 75
3B-d-6 C21H16ClN5O3 2.78 >300 80
3B-d-7 C29H22ClN5O2 3.77 >300 85
3C-d-1 C23H17ClN6O4 2.78 295-297 86
3C-d-2 C24H20N6O4 3 255-257 56
3C-d-3 C24H19N7O6 2.67 225-227 50
3C-d-4 C23H21N6O4 3.22 260-262 72
3C-d-5 C25H25N6O4 2.89 >300 65
3C-d-6 C21H16N6O5 2.56 >300 62
3C-d-7 C29H22N6O4 3.55 >300 80
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Neurotoxicity (NT) screening
The activity of the drugs interfering with motor coordination was 
checked by the rotarod test. The mice will train to stay on an accelerating 
rotarod that rotates at 6 revolutions per minute. Trained animals were 
given ip injection of the test compounds in doses of 30, 100, 300 mg/kg. 
The rod diameter was 3.2 cm. NT indicated by the inability of the animal 
to maintain equilibrium on the rotarod for at least 1 minute in each of 
three trials. The dose, at which the animals were unable to grasp the 
rotarod, will determine. All the results were reported in Table 3.
RESULTS AND DISCUSSIONS
Chemistry
A series of new quinazolinone derivatives 3A-d (1-7), 3B-d (1-7), and 
3C-d (1-7) have been synthesized using appropriate routes. All newly 
synthesized compounds were characterized on the basis of their 
m.p, Rf value (data are shown in Table 2), Fourier transform infrared, 
1H NMR, and elemental analysis. From the structural investigation, 
IR spectra showed the stretching frequency range between 1580 and 
1620/cm, which showed the presence of imine linkage and also the 
absence of -NH2 peak for the synthesized quinazolinone semicarbazone 
derivatives. Dependent substitution of double bonded nitrogen group 
of imine C=N could be the reason for the characteristic absorption 
close to the carbonyl C=O of amide (1632-1685 cm−1) or C=C of alkene 
(1600-1680/cm) double bond stretching region. 1H-NMR spectra 
give a characteristic proton resonance shifts for all the synthesized 
quinazolinone semicarbazone derivatives, which ensured the existence 
of aromatic, amine, amide, and imine protons. Almost all the synthesized 
analog showed potent anticonvulsive activity.
Design
The conformational analysis of the older generation clinically 
active anticonvulsant drugs such as phenytoin, phenobarbitone, 
carbamazepine, lamotrigine, rufinamide, and remacemide led to the 
proposal of a general model for anticonvulsant activity comprising 
of two aromatic rings or they are equivalent in a favored orientation 
and the third region containing a hydrogen bond-forming functional 
groups in terms of interaction at the binding site as proposed by 
Dimmock et al. [43]. All the synthesized compounds comprise these 
essential pharmacophoric requirements that are important for good 
anticonvulsant activity.
Pharmacology
Quinazolinone heterocycles are the attractive scaffold as anticonvulsant 
agents as well as various CNS activities [52,53]. We have designed a 
novel quinazolinone semicarbazones. In the pharmacological study, 
we have investigated anticonvulsant activity as well as the NT. All the 
synthesized compounds were screened for their anticonvulsant activity 
using various chemical induced convulsion models using strychnine, 
thiosemicarbazide and 4-aminopyridine to induced convulsion, 
diazepam and phenytoin were used as the standard drug at the dose 
of 30, 100, 300 mg/kg b.w. anticonvulsant activity and NT data for the 
semicarbazones of quinazolinone derivatives 3A-d (1-7), 3B-d (1-7), 
3C-d (1-7) are given in Table 3, and most of the compounds showed 
mild to moderate anticonvulsant activity. The analogs 3A-d-5, 3B-d-5, 
and 3C-d-5 were active at 30 mg/kg and 100 mg/kg only at 0.5 h and 
1 h, indicating that they have the rapid onset of action and shorter 
duration of action and were exhibit moderate anticonvulsant activity. 
The compounds 3A-d-4, 3B-d-4, 3C-d-4 were observed to be most 
active for anticonvulsant activity. All the compounds showed activity 
against chemo shock method pinpointing their capability to prevent 
seizure spread.
SAR
It also showed that a substituted aromatic ring in position 3 is 
significant for anticonvulsant activity. Various N-1(substituted-N-4[(4-
oxo-3-phenyl-3, 4-dihydro-quinazoline-2-ylmethyl) semicarbazones 
derivatives 3A-d (1-7), 3B-d (1-7), 3C-d (1-7) were synthesized to 
establish the pharmacophoric substituents, responsible for the activity.
Table 3: Anticonvulsant evaluation and neurotoxicity screenings of new quinazolinone semicarbazone derivatives 3A-d (1-7), 3B-d (1-7), 
3C-d (1-7) in the strychnine, thiosemicarbazide, 4-aminopyridine induce model after intraperitoneal injection in mice







0.5 h 1 h 2 h 0.5 h 1 h 2 h 0.5 h 1 h 2 h 0.5 h 4 h
Controls - - - - - - - - - - -
Compound ID
3A-d-1 30 - - 30 - - 30 - 100 -
3A-d-2 30 - - 30 - - 30 - - 100 -
3A-d-3 30 - - 30 - - - - - 100 -
3A-d-4 300 100 100 300 100 30 100 30 - 300 300
3A-d-5 30 100 - 30 100 - 30 30 - 300 -
3A-d-6 30 30 - - - - - - - 30 30
3A-d-7 30 - - - - - - - - 300 -
3B-d-1 30 - - 100 - - 30 - - 30 -
3B-d-2 30 - - 30 - - 30 - - 30 -
3B-d-3 30 - - 30 - - - - - 100 -
3B-d-4 300 100 100 300 100 30 100 100 30 300 300
3B-d-5 30 30 - 100 30 - 30 30 - 100 -
3B-d-6 30 - - 30 - - - - - 30 -
3B-d-7 30 - - - - - - - - 100 -
3C-d-1 30 - - 30 - - 30 - - 100 -
3C-d-2 30 - - 30 - - 30 - - 30 -
3C-d-3 30 - - 30 - - - - - 100 -
3C-d-4 300 100 100 300 100 30 100 30 30 300 300
3C-d-5 100 30 - 100 100 - 30 30 - 30 -
3C-d-6 30 30 - 30 - - - - - 30 100
3C-d-7 30 - - - - - - - - 30 -
Diazepam (mg/kg) 10 10 10 10 10 10 - - -
Phenytoin (mg/kg) 30 30 30
n=10, test compounds were suspended in polyethylene glycol and doses of 30, 100, 300 mg/kg were administered through intraperitoneal (i.p.) injection in mice. The 
figures in the table indicate the dose in mg/kg at which bioactivity was observed in a majority of the animals. The dash (-) indicates an absence of activity at maximum dose 
administered (300 mg/kg), In neurotoxicity screen the figure indicate the dose at which no neurotoxicity was observed and the dash (-) indicates compounds was not tested
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The aryl/cyclohexyl ring acts as a lipophilic domain, C=O group acts as 
electron donor, NH groups act as hydrogen bonding domain, and the 
aryl substituent acts as the distal hydrophobic center Fig. 1. Thus, it may 
be stated that compounds 3A-d (1-7), 3B-d (1-7), 3C-d (1-7) fulfill the 
essential pharmacophoric requirements for anticonvulsant activity.
Compounds 3A-d-5, 3B-d-5, 3C-d-5 displayed moderate and compounds 
3A-d-4, 3B-d-4, 3C-d-4 most protection in chemo shock models 
study and supported the pharmacophoric character of cyclohexyl 
moiety for anticonvulsant activity. This observation supports the 
fact that substitution on the aryl ring by halogen led to a number of 
semicarbazones with low ED50 value and high protective index value. 
This observation also indicated the role of electronic factors affecting 
anticonvulsant activity.
CONCLUSION
In this paper, we have attempted to design and synthesized novel 
quinazolinone derivatives that exhibit anticonvulsant activity. The 
results obtained revealed that numbers of novel quinazolinone 
derivatives effective in chemical induce (chemo shock) model, 
compounds 3A-d-4, 3B-d-4, 3C-d-4 showed the most active while 
3A-d-5, 3B-d-5, 3C-d-5 moderate activity and remaining compounds 
showed mild activity. This study provides the broad-spectrum 
anticonvulsant activity of substituted quinazolinone semicarbazones 
that are comparatively higher or equipotent to the currently available 
drugs in the comparison tests. Overall, the synthesized compounds 
emerged as more active and less neurotoxic derivatives.
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